2,2'-(4-羟基苯亚甲基)二[4-(5-甲基-1H-四唑-1-基亚氨基甲基)苯酚] | 235106-62-4

• 物质功能分类: 原料药 - 抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 2,2'-(4-羟基苯亚甲基)二[4-(5-甲基-1H-四唑-1-基亚氨基甲基)苯酚]
• 英文名称: 2-[[2-hydroxy-5-[(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(5-methyltetrazol-1-yl)iminomethyl]phenol
• CAS: 235106-62-4
• 化学式: C₂₅H₂₂N₁₀O₃
• 分子量: 510.5
• InChiKey: BLUJRJMLDHEMRX-UHFFFAOYSA-N

物化性质

• 熔点：
  >225°C (dec.)
• 沸点：
  816.7±75.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)
• 溶解度：
  碱性溶液（微溶），DMSO（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  173
• 氢给体数：
  3
• 氢受体数：
  11

制备方法与用途

生物活性

体外研究显示，VP 14637对75种RSV A和B亚型的临床分离株具有抗病毒活性。

用途

VP-14637是一种融合抑制剂，临床前研究证明它可以有效阻断RSV感染。

文献信息

• COMBINATION PRODUCTS FOR THE TREATMENT OF RSV
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：EP3892273A2

  公开（公告）日：2021-10-13

  The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1-cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2-ethylsulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2-one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2-yl)nicotinamido)benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-3H-imidazo[4,5-h]isoquinoline-7,9(6H,8H)-dione , for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Compound B, the use of the combination of Compound A and one or more of Compound B - or the pharmaceutical product comprising Compound A and one or more Compound B - for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.

  本发明涉及 RSV 抑制化合物 A 的组合，即3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one,和一种或多种 RSV 抑制性化合物 B，选自利巴韦林、GS-5806、MDT-637、BTA-9881、BMS-433771、YM-543403、A-60444、TMC-353121、RFI-641、CL-387626、MBX-300、AZ-27、MEDI8897、CR9501、帕利维珠、Palivizum、CR9501, palivizumab, 3-(5-氯-1-[3-(甲磺酰)丙基]-1H-苯并咪唑-2-基}甲基)-1-环丙基-1,3-二氢-2H-咪唑并[4,5-c]吡啶-2-酮、3-[[7-chloro-3-(2-ethylsulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2-one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]壬烷-2-基)烟酰胺基)苯甲酰基)-5,6-二氢-4H-苯并[b]噻吩并[2,3-d]氮杂卓-2-甲酰胺，以及 4-氨基-8-[3-[[2-(3,4-二甲氧基苯基)乙基]氨基]丙基]-6、6-二甲基-2-(4-甲基-3-硝基苯基)-3H-咪唑并[4,5-h]异喹啉-7,9(6H,8H)-二酮，用于治疗或改善 RSV 感染。本发明进一步涉及化合物 A 和一种或多种化合物 B 的组合物、包含化合物 A 和一种或多种化合物 B 的药物产品、化合物 A 和一种或多种化合物 B 的组合物--或包含化合物 A 和一种或多种化合物 B 的药物产品--用于治疗 RSV 感染的用途，以及治疗或改善有需要的受试者 RSV 感染的方法，该方法包括向所述受试者施用有效量的化合物 A 和一种或多种化合物 B 的组合物。
• Combination products for the treatment of RSV
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US10363253B2

  公开（公告）日：2019-07-30

  The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1 cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2 yl)nicotinamido)benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl 3-nitrophenyl)-3H-imidazo[4,5-h]isoquinoline-7,9(6H,8H)-dione, for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Compound B, the use of the combination of Compound A and one or more of Compound B—or the pharmaceutical product comprising Compound A and one or more Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.

  本发明涉及 RSV 抑制化合物 A 的组合，即3-(5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one,和一种或多种 RSV 抑制化合物 B，选自利巴韦林、GS-5806、MDT-637、BTA-9881、BMS-433771、YM-543403、A-60444、TMC-353121、RFI-641、CL-387626、MBX-300、AZ-27、MEDI8897、CR9501、帕利珠单抗，3-(5-氯-1-[3-(甲磺酰)丙基]-1H-苯并咪唑-2-基}甲基)-1-环丙基-1,3-二氢-2H-咪唑并[4,5-c]吡啶-2-酮、3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]壬烷-2-基)烟酰胺基)苯甲酰基)-5,6-二氢-4H-苯并[b]噻吩并[2,3-d]氮杂卓-2-甲酰胺，以及 4-氨基-8-[3-[[2-(3,4-二甲氧基苯基)乙基]氨基]丙基]-6、6-二甲基-2-(4-甲基-3-硝基苯基)-3H-咪唑并[4,5-h]异喹啉-7,9(6H,8H)-二酮，用于治疗或改善 RSV 感染。本发明进一步涉及化合物 A 和一种或多种化合物 B 的组合物、包含化合物 A 和一种或多种化合物 B 的药物产品、化合物 A 和一种或多种化合物 B 的组合物或包含化合物 A 和一种或多种化合物 B 的药物产品用于治疗 RSV 感染的用途，以及治疗或改善有需要的受试者 RSV 感染的方法，该方法包括向所述受试者施用有效量的化合物 A 和一种或多种化合物 B 的组合物。